Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MP-376 (Aeroquin) vs tobramycin inhalation in stable cystic fibrosis patients
2010-019634-26Phase 3Completed
- Sponsor
- Mpex Pharmaceuticals, Inc.
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of levofloxacin inhalation solution in cystic fibrosis (CF) and Pseudomonas aeruginosa pulmonary infection (2 arms), sponsored by Mpex Pharmaceuticals, Inc. Primary endpoint: Primary Analysis - Safety comparison. Started Jan 2011; status: completed.
02
Drugs
levofloxacin inhalation solution
03
Conditions
cystic fibrosis (CF)Pseudomonas aeruginosa pulmonary infection
Beyond the preview
Go deeper on 2010-019634-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019634-26.